NASD · Healthcare · Biotechnology · USA
Stoke Therapeutics Inc is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
Stoke Therapeutics is a clinical company developing RNA-based medicines to address underlying causes of severe genetic diseases by restoring protein levels through its TANGO approach. The company is advancing zorevunersen, an antisense oligonucleotide in testing for Dravet syndrome, a severe genetic epilepsy affecting children. Stoke is also developing candidates for other genetic diseases of the central nervous system and eye.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Stoke Therapeutics Inc stock.
Overvalued: intrinsic value $3.71 per share, market price $24.82, margin of safety -568.1% (as of 2026-10-19).
Its liquidation floor, current assets minus every liability, values the shares at $3.71; the price of $24.82 is 568% above that value.
17 more funds hold it; the full list is part of the paid plan.
102 more in this industry show a wider margin of safety.
STOK is overvalued (as of the 2026-10-19 close). Its liquidation floor, current assets minus every liability, values the shares at $3.71; the price of $24.82 is 568% above that value.
$3.71 per share (as of the 2026-10-19 close), against a market price of $24.82. That is a margin of safety of -568.1%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.